Aripiprazole: Examining the Clinical Implications of D2 Affinity

被引：0
|
作者：
Anam, Adiba [1 ]
Lynch, Sean [1 ]
Mosharraf, Nafiz [1 ]
Soukas, Chloe [1 ]
Gekhman, Dmitriy [1 ,2 ]
机构：
[1] Mt Sinai Beth Israel, Dept Psychiat, New York, NY USA
[2] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA
来源：
CNS SPECTRUMS | 2023年 / 28卷 / 02期
关键词：
D O I：
10.1017/S1092852923001232
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Aripiprazole: examining the clinical implications of D2 affinity
    Anam, Adiba
    Lynch, Sean
    Mosharraf, Nafiz
    Soukas, Chloe
    Gekhman, Dmitriy
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2023, 38 (02) : 110 - 113
  • [2] Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Xu, C
    Ryan, E
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01): : 381 - 389
  • [3] Combining Aripiprazole and Haloperidol: Focus on D2 Receptor
    Crapanzano, Calogero
    Laurenzi, Pier Francesco
    Amendola, Chiara
    Casolaro, Ilaria
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (07): : 918 - 918
  • [4] Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications
    van Wieringen, Jan-Peter
    Booij, Jan
    Shalgunov, Vladimir
    Elsinga, Philip
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 (02) : 135 - 154
  • [5] Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications
    Jan-Peter van Wieringen
    Jan Booij
    Vladimir Shalgunov
    Philip Elsinga
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386 : 135 - 154
  • [6] Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
    Keck, PE
    McElroy, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (04) : 655 - 662
  • [7] Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole
    Kwon, Jun Soo
    Kim, Euitae
    Kang, Do-Hyung
    Choi, Jung Seok
    Yu, Kyung-Sang
    Jang, In-Jin
    Shin, Sang-Goo
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (12) : 897 - 907
  • [8] Aripiprazole acts as a selective dopamine D2 receptor partial agonist
    Wood, Martyn
    Reavill, Charlie
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) : 771 - 775
  • [9] Aripiprazole:: a partial agonist at D2 receptors in rat pituitary cells
    Hirose, T
    Inoue, Y
    Okazaki, H
    Tottori, K
    Stark, A
    Kikuchi, T
    Kitagawa, H
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : A13 - A13
  • [10] Interactions of the novel antipsychotic, aripiprazole, at the D2 dopamine receptor.
    Prioleau, C
    Lawler, CP
    Mailman, RB
    FASEB JOURNAL, 1998, 12 (04): : A456 - A456
12345